Rezpeg Shows Durable Response at One Year, Phase 3 AA Trial Set for Early 2027
NKTR sits 81% above its 52-week low of $33.4.
Summary
Nektar's rezpegaldesleukin showed durable and deepening responses through one year of treatment in alopecia areata. At 6 months off treatment, 63% maintained SALT score ≤20 and 19% achieved SALT score ≤10, up from 7% at 52 weeks. Safety remained favorable. The company will initiate a Phase 3 ZENITH AA study in early 2027. This follows the $90 million jury verdict against Eli Lilly over rezpeg, strengthening Nektar's position in the drug's development.
Updates
· SEC 8-K — The 8-K includes the EADV presentation showing 75% maintained SALT ≤20 at 4 months off treatment and 63% at 6 months, with 19% achieving SALT ≤10.
At the time of this announcement, NKTR was trading at $60.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $33.40 to $109.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.